Investors
Genomic Health, Inc. (NASDAQ: GHDX) is a global cancer company focused on the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.
Genomic Health Corporate Presentation (May 10, 2013)
View all » 
Recent Press Releases
View all »Webcasts & Presentations
May 14, 2013 at 5:00 PM ET
Genomic Health to Present at Bank of America Merrill Lynch Health Care Conference
May 10, 2013
Genomic Health Corporate Presentation
May 8, 2013 at 1:00 PM PT
Webcast to Review Positive Clinical Validation and Development of the Oncotype DX® Prostate Cancer Test
May 2, 2013 at 1:30 PM PT
Genomic Health First Quarter 2013 Financial Results Webcast
DISCLAIMER
The information in the fact sheet, press releases and webcasts should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.
Forward-Looking Statements
This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.
